Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Lisa Pickard
Lisa.Pickard@icr.ac.uk


Dr Udai Banerjii
udai.banerji@icr.ac.uk


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Tissue collection protocol RE-THINK CANCER V2

Tissue collection protocol RE-THINK CANCER V2

Recruiting

Open to: Female / Male

Age: 18 Years - 100 Years

Medical Conditions

Malignant neoplasms of ill-defined, secondary and unspecified sites


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Treatment for advanced cancers often consists of administering anticancer drugs. Apart from a few exceptions, cancer at this stage is not curable and the cancer cells within the tumours become resistance to anticancer drugs. This project studies two aspect of anticancer drug resistance.

The first aspect is due to re-wiring of signal transduction. Signal transduction is a method cancer cells use to send information from the outside of the cancer cells to the inside of the cell. Certain anticancer drugs block this flow of information; however cells find ways of re-routing this information within the cancer cells and become resistant as they have found 'escape' routes of sending information. Understanding and predicting these escape routes will help researchers design combination treatments to stop or delay cancer cells to become resistant to anticancer drugs.

The second part of the project involves herding of clonal evolution. When a tumour (lump made of cancer cells) is treated with anticancer drugs, some of the cells undergo changes in their building blocks or genes and evolve into cancer cells that are resistant. The resistant cancer cells then divide and the next generations of cancer cells are also resistant and this process is called clonal evolution of resistant cancer cells. Studying and understanding how cancer cells evolve can allow researchers to make cancer cells grow into a state that can be killed by use of other known anticancer drugs. Making cancer cells grow into a specific type that can be treated with existing anticancer drugs is called clonal herding. This aspect of the research will help us decide the best order to go give different anticancer drugs to a patient.

This protocol allows collection of cancer tissue to conduct preclinical experiments.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

20 Jul 2020 30 Dec 2027

Observational

Observational type: Clinical Laboratory Study;



You can take part if:



You may not be able to take part if:


1. All the sample is required to establish a diagnosis or standard of care. 2. Any bleeding diathesis or anatomical factors (e.g. close to major blood vessel) which would make biopsy/drainage of fluid for research purposes dangerous.


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Royal Marsden Hospital (surrey)
    Sutton
    Surrey
    SM2 5PT

Lisa Pickard
Lisa.Pickard@icr.ac.uk


Dr Udai Banerjii
udai.banerji@icr.ac.uk



The study is sponsored by Institute of Cancer Research: Royal Cancer Hospital and funded by NIHR Academy .




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details

for Trial ID: CPMS 44251

Last updated 21 July 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.